Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study.

[1]  Dan-Qin Sun,et al.  Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis , 2023, eGastroenterology.

[2]  Yunlei Deng,et al.  Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. , 2023, Journal of hepatology.

[3]  A. Tybjaerg-hansen,et al.  Genetic risk of fatty liver disease and mortality in the general population: A Mendelian randomization study , 2023, Liver international : official journal of the International Association for the Study of the Liver.

[4]  B. Sangro,et al.  Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment , 2023, Journal of Physiology and Biochemistry.

[5]  R. D. de Knegt,et al.  Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality , 2023, Hepatology (Baltimore, Md.).

[6]  S. Sarin,et al.  The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease , 2023, Therapeutic advances in endocrinology and metabolism.

[7]  C. Chen,et al.  Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis , 2022, Frontiers in Endocrinology.

[8]  Hokyou Lee,et al.  Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population , 2022, Hepatology International.

[9]  Shuohua Chen,et al.  Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. , 2021, The Journal of clinical endocrinology and metabolism.

[10]  U. Schwab,et al.  Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis , 2021, Nutrients.

[11]  S. Lorkowski,et al.  Alcohol consumption and mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. , 2021, Atherosclerosis.

[12]  Donghee Kim,et al.  Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. , 2021, Journal of hepatology.

[13]  C. Datz,et al.  Diet and exercise in NAFLD/NASH: Beyond the obvious , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[14]  M. Nguyen,et al.  Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  G. Perseghin,et al.  Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[16]  Z. Younossi,et al.  AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease (NAFLD): Expert Review. , 2020, Gastroenterology.

[17]  Yong‐ho Lee,et al.  Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[19]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[20]  T. Cotter,et al.  NAFLD 2020: The State of the Disease. , 2020, Gastroenterology.

[21]  A. Isaacs,et al.  Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality , 2019, Diabetologia.

[22]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[23]  L. Carlsson,et al.  Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver , 2017, Journal of internal medicine.

[24]  J. Mi,et al.  Relationship of Alcohol Consumption to All-Cause, Cardiovascular, and Cancer-Related Mortality in U.S. Adults. , 2017, Journal of the American College of Cardiology.

[25]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[26]  F. Nascimbeni,et al.  Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.

[27]  H. Bang,et al.  Non–Laboratory-Based Self-Assessment Screening Score for Non-Alcoholic Fatty Liver Disease: Development, Validation and Comparison with Other Scores , 2014, PloS one.

[28]  Sowmya R. Rao,et al.  Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. , 2010, Journal of the American College of Cardiology.

[29]  C. L. Hart,et al.  Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies , 2010, BMJ : British Medical Journal.

[30]  C. Hayward,et al.  Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: modification by insulin resistance. , 2005, The Journal of clinical endocrinology and metabolism.